|
|
Á¦¸ñ :
[Áö¿£Æ¼Æĸ¶]GNT Pharma Provides Update on Two Phase III Studies of Nelon |
|
±Û¾´ÀÌ : Smith |
ÀÛ¼ºÀÏ : 2022-09-27 01:09:46 |
Á¶È¸¼ö : 1039
|
|
|
|
GNT Pharma Provides Update on Two Phase III Studies of Nelonemdaz for Acute Ischemic Stroke Patients Treated with tPA (ENIS-3) or Endovascular Thrombectomy (RODIN)
GNT Pharma Co., Ltd
September 19, 2022, 10:00 pm
GNT Pharma Co., Ltd
Promising efficacy and safety profiles were observed in prior Phase II studies in acute ischemic stroke patients treated with recanalization therapies.
The ENIS-3 trial has achieved >33% of target enrollment (948 patients). The independent data monitoring committee (IDMC) has completed interim analysis and indicated that the trial should continue.
The RODIN trial has achieved >45% of target enrollment (496 patients) in 7 months.
YONGIN, South Korea, Sept. 19, 2022 (GLOBE NEWSWIRE) -- GNT Pharma Inc. announces that the independent data monitoring committee (IDMC) for ENIS-3 (Efficacy and safety of Nelonemdaz for Ischemic Stroke) has completed a pre-specified interim analysis encompassing 227 acute ischemic stroke patients treated with placebo or nelonemdaz within 8 hours of onset in China. The IDMC concluded that the ENIS-3 trial should continue as planned without modification.
Áö¿£Æ¼Æĸ¶ ÁÖÁÖµ¿È£È¸ ¹Ù·Î°¡±â
¡Ø Åä·Ð¹æÀÇ ±ÛÀº ³×ƼÁðÀÌ ÀÛ¼ºÇÑ ±Û·Î ´ç»ç¿Í ÀüÇô ¹«°üÇϸç ÃÖÁ¾Ã¥ÀÓÀº ÀÌ¿ëÀÚ¿¡°Ô ÀÖ½À´Ï´Ù. |
|
|
|
|
|
|
|
[Áö¿£Æ¼Æĸ¶]GNT Pharma Provides Update on Two Phase III Studies of Nelon,
Loading Time [ 0.07 Sec ] stock |
|
ºñ»óÀåÁֽİŷ¡, Àå¿ÜÁֽĽÃÀå NO.1 38Ä¿¹Â´ÏÄÉÀÌ¼Ç (http://www.38.co.kr)
±¤°í ¹®ÀÇ : ¢Ï 1644-3830 (38Ä¿¹Â´ÏÄÉÀ̼Ç) |
Àå¿ÜÁÖ½Ä,ºñ»óÀåÅä·Ð¹æ,Áö¿£Æ¼Æĸ¶ ÁÖÁÖÅä·Ð¹æ,Áö¿£Æ¼Æĸ¶ ±â¾÷°³¿ä,Áö¿£Æ¼Æĸ¶ ÇöÀç°¡,Áö¿£Æ¼Æĸ¶ ÁÖ°¡,Áö¿£Æ¼Æĸ¶ °ü·Ã´º½º,Áö¿£Æ¼Æĸ¶ ÁÖ½Ä,Áö¿£Æ¼Æĸ¶ ±â¾÷°¡Ä¡,Áö¿£Æ¼Æĸ¶ ½ÇÀû,Áö¿£Æ¼Æĸ¶ ÁÖ´ç¼øÀÌÀÍ,Áö¿£Æ¼Æĸ¶ ¸ÅÃâ,Áö¿£Æ¼Æĸ¶ »óÀå,38Ä¿¹Â´ÏÄÉÀ̼Ç,»ïÆÈÄ¿¹Â´ÏÄÉÀ̼Ç,38stock,38,ºñ»óÀå,ºñ»óÀåÁÖ½Ä,Àå¿ÜÁÖ½Ä,Àå¿Ü½ÃÀå,¼Ò¾×ÁÖÁÖ¸ðÀÓ,ÀÎÅͳݰø¸ð,ºñ»óÀåÁֽİŷ¡,Àå¿ÜÁֽĽü¼,Àå¿ÜÁֽİŷ¡,Àå¿Ü°Å·¡,ºñ»óÀåÁֽĸŸÅ,ºñ»óÀå½Ã¼¼,Àå¿Ü½Ã¼¼,Àå¿ÜÁֽĽÃÀå,ÁÖÁÖµ¿È£È¸,ºñ»óÀåÁֽĽü¼,Àå¿ÜÁֽĽÃȲ,IPO°ø¸ðÁÖ,ÀÎÅͳݰø¸ðÁÖ,IPO,»óÀ忹Á¤,½ºÆÑ,°ø¸ðÁÖ,±â¾÷°ø°³,°ø¸ð°ø¸ðû¾àÀÏÁ¤,½Å±Ô»óÀå,°ø¸ðÁÖû¾à,Àå¿Ü½ÃȲ,Àå¿ÜÁֽĽÃÀå,ºñ»óÀå»ç,ºñ»óÀåȸ»ç,ºñ»óÀå±â¾÷,ÇÁ¸®º¸µå,3½ÃÀå,ÄÚ½ºÄÞ,Äڳؽº,KONEX,KOSCOM,ÆŽº³Ý,Á¦3ÁֽĽÃÀå,KOSDAQ,KOSPI,»ï¼ºsds,Àå¿ÜÅõÀÚ,Àå¿ÜÁֽĻçÀÌÆ®,¼Ò¾×ÁÖÁÖ¸ðÀÓ,ºñ»óÀåÁֽİŷ¡»çÀÌÆ®
| |
|